Clinical Scorecard: Increased Risk of Invasive Carcinomas Linked to Inflammatory Bowel Disease in a Mouse Model of ATF6-Driven Colon Cancer
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD) and Colitis-Associated Cancer (CAC)
Key Mechanisms
Chronic inflammation and microbiota-dependent activation of ATF6-mediated unfolded protein response leading to colonic tumorigenesis
Target Population
Patients with IBD, particularly those with active disease and altered microbiota
Care Setting
Research and clinical settings focusing on IBD and colorectal cancer risk
Key Highlights
IL-10 deficiency in mice increases susceptibility to ATF6-driven colonic adenomas and invasive carcinomas.
Tumor formation is microbiota-dependent, with mucosal immune cell infiltration and dysbiosis contributing to carcinogenesis.
Increased ATF6 expression is observed in IBD patients during active disease, supporting human relevance of the mouse model.
Guideline-Based Recommendations
Diagnosis
Consider assessment of ATF6 expression levels in colonic tissues during active IBD to identify early dysplastic changes.
Evaluate mucosal microbiota composition near tumor sites rather than relying solely on stool samples for microbial risk assessment.
Management
Target chronic inflammation and modulate microbiota to reduce ATF6-driven tumorigenesis risk in IBD patients.
Monitor and potentially restore IL-10 signaling pathways to mitigate inflammation-induced tumor susceptibility.
Monitoring & Follow-up
Regular surveillance colonoscopy with biopsy to detect early adenomas or carcinomas in IBD patients with elevated ATF6 expression.
Monitor mucosal immune cell infiltration and microbial dysbiosis as indicators of tumorigenic progression.
Risks
Chronic ER stress and unfolded protein response activation via ATF6 can promote inflammation and cancer development.
Dysbiosis with increased pathobionts such as Enterobacteriaceae and genotoxin-producing E. coli strains increases CRC risk.
Patient & Prescribing Data
Mouse model of IEC-specific activated ATF6 with IL-10 deficiency mimicking IBD-related tumorigenesis
IL-10 deficiency and microbiota composition critically influence ATF6-driven tumor development, suggesting therapeutic targeting of inflammation and microbiota may reduce cancer risk.
Clinical Best Practices
Incorporate evaluation of ER stress markers such as ATF6 in IBD patients to identify those at higher risk for CAC.
Use mucosal biopsies for microbiota analysis to better understand tumor-associated microbial changes.
Consider interventions that restore IL-10 function or modulate microbiota to prevent progression from inflammation to cancer.
by Janine Kövilein, Adam Sorbie, Sevana Khaloian, Vanessa Küntzel, Miriam von Stern, Mohamed Ahmed, Sebastian Jarosch, Marianne Remke, Amira Metwaly, Elena M Reuss, Dirk H Busch, Matthieu Allez, Katja Steiger, Barbara Schraml, Olivia I Coleman, Dirk Haller
